OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)

Article	Citations
	1495
Reply: Fiber and whole grain intakes in relation to liver cancer risk—An analysis in 2 prospective cohorts and systematic review and meta-analysis of prospective studies	1305
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death	1199
Retracted	741
Effectiveness and safety of glecaprevir/pibrentasvir for 8 weeks in the treatment of patients with acute hepatitis C: A single-arm retrospective study	496
Letter to the editor: The precise relationship between MELD and survival without a liver transplant	425
Cover Image	334
Letter to the editor: The role of aquaporin 9 in modeling of ornithine transcarbamylase deficiency	326
Late-Breaking Abstracts	281
Boosting Success: Optimizing Thiopurine Therapy in Autoimmune Hepatitis With Allopurinol	253
Post-vax vein vigilance: Unmasking splanchnic thrombosis risks	218
Acute encephalopathy without hyperammonemia has a different presentation than overt HE and displays a similarly severe prognosis	196
Higher level of Hepatitis B Surface antigen associated with delayed development of hepatocellular carcinoma in immune-tolerant patients	192
Hepatic encephalopathy—We are no longer those who believe that reality is what we perceive	191
Moving beyond the liver – proteomics as a molecular footprint of systemic damage in metabolic dysfunction-associated steatotic liver disease	182
Letter to the Editor: Regarding terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury	171
Requirement of RORα for maintenance and antitumor immunity of liver‐resident natural killer cells/ILC1s	170
Hepatocyte‐specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin‐like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice	169
Changing epidemiology of hepatocellular cancer in the United States: Winning the battle but it is not over yet	162
Letter to the editor: Treatment options for 3–5‐cm solitary HCC—Need a closer look!	155
Letter to the editor: Beneath the surface of the pandemic: Persons with alcohol‐associated liver disease need our attention	155
REPLY:	153
Alan Hofmann (1931‐2021): A career well spent understanding bile acids	151
Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma	148
Reply	147

Letter to the Editor: LO2, a misidentified cell line: Some data should be interpreted with caution	144
PGD2/DP1 axis promotes liver regeneration by secreting Wnt2 in KCs in mice	143
Reply: Can pFIB scores reliably exclude significant liver fibrosis in pediatric MASLD?	141
More immunosuppressive, more immunotherapy responsive? A double-edged sword of HBV-induced immune response in HCC	133
Letter to the editor: Targeted decrease of portal hepatic pressure gradient immediately after TIPS improves ascites control and prognosis	133
Letter to the Editor: Insurance should cover vancomycin for primary sclerosing cholangitis	129
Reply: Medications promoting abstinence in alcohol-associated cirrhosis	122
Letter to the Editor: The Hepa 1–6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy	122
Precipitous changes in nomenclature and definitions—NAFLD becomes SLD: Implications for and expectations of AASLD journals	121
Obituary for Roberto J. Groszmann—The Father of Portal Hypertension	117
Group‐2 Innate Lymphoid Cells Promote HCC Progression Through CXCL2‐Neutrophil‐Induced Immunosuppression	117
Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model	116
Stellate cell-specific adhesion molecule protocadherin 7 regulates sinusoidal contraction	115
Gastrodin Improves Nonalcoholic Fatty Liver Disease Through Activation of the Adenosine Monophosphate–Activated Protein Kinase Signaling Pathway	115
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophages to improve chemotherapy efficacy against liver tumor	115
Multiomics approaches for identifying the PANoptosis signature and prognostic model via a multimachine-learning computational framework for intrahepatic cholangiocarcinoma	115
Efficacy and safety of infliximab in patients with autoimmune hepatitis	114
Access to technology to support telehealth in areas without specialty care for liver disease	109
Switch‐associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1	108
Regulatory role and translational potential of CCL11 in liver fibrosis	105
Reply: Liver stiffness progression comparison between diabetics and non-diabetics with biopsy-proven metabolic dysfunction-associated steatosis	104
Implementation of a controlled human infection model for evaluation of HCV vaccine candidates	104
NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH	102
Plasma proteomic signature of fatty liver disease: The Rotterdam Study	102
AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease	102
Comparison of pharmacological therapies in metabolic dysfunction–associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis	101
	99
Letter to the Editor: Comparative efficacy of pharmacologic therapies for MASH in reducing liver fat content—Systematic review and network meta-analysis	98
	97
Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma	97
Instructions to Authors	95
Letter to the Editor: Primary sclerosing cholangitis and autoimmune hepatitis—Distinct or common autoimmune penetrance?	95
Letter to the Editor: Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatm	95
Understanding advanced cystic fibrosis liver disease through genetic variation: Where do the pathways lead and how much further must we go?	94
Letter to the editor	94
Healthy peribiliary glands are necessary for successful liver transplantation	93
Erratum	92
Dedifferentiation‐associated inflammatory factors of long‐term expanded human hepatocytes exacerbate their elimination by macrophages during liver engraftment	90
Endpoints and New Options for Treatment of Chronic Hepatitis D	87
Deciphering the spatial tumor microenvironment in intrahepatic cholangiocarcinoma	85
Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study	85
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis	84
Tumor-derived CCL2 drives tumor growth and immunosuppression in IDH1-mutant cholangiocarcinoma	83
Erratum: AASLD Practice Guidance on Acute-on-chronic liver failure and the management of critically ill patients with cirrhosis	83
Letter to the editor: Is PAI‐1 a thrombotic biomarker in NASH cirrhosis?	82
Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty	80
Reply	79
Letter to the Editor: Overlooking the important factor: Hypoxia	79
Magnetic resonance elastography for prediction of long‐term progression and outcome in chronic liver disease: A retrospective study	78
In vivo imaging of calcium dynamics in zebrafish hepatocytes	78

REPLY:	76
Extracellular Signal‐Regulated Kinase 5 Regulates the Malignant Phenotype of Cholangiocarcinoma Cells	76
MRI‐Based Iron Phenotyping and Patient Selection for Next‐Generation Sequencing of Non–Homeostatic Iron Regulator Hemochromatosis Genes	76